Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
Eli Lilly reported 48% revenue growth in the second quarter of 2026 and lifted its full-year outlook, but the stock was trading at 30.94 times forward earnings as of Oct. 6, below its longer-run average multiple, according to a market report.
THE APEX TIMES
THE APEX TIMES
A newly announced research collaboration and licensing arrangement with Eli Lilly is putting InnoCare Pharma back in investors’ focus, with analysts weighing whether the market is underpricing the potential of up to five drug targets aimed at unmet medical needs.
THE APEX TIMES
A key question for investors ahead of Eli Lilly’s next earnings report is whether growth from newer oncology treatments can offset softer momentum in Verzenio and the natural decline of older therapies, as the company’s portfolio evolves.
THE APEX TIMES
Instead of trying to single out individual drug makers, a Yahoo Finance market story argues that investors can gain broad exposure to healthcare using a diversified exchange-traded fund approach.
THE APEX TIMES
A market recap in Yahoo Finance’s stock coverage uses Eli Lilly’s performance over the past 10 years to illustrate how patient, buy-and-hold investors can benefit from compounding gains.
THE APEX TIMES
Eli Lilly’s (LLY) stock has crossed above its 50-day simple moving average, a chart announcement that some market participants interpret as a shift toward stronger near-term momentum.
THE APEX TIMES
A third-quarter 2026 investor letter from Andrew Hill Investment Advisors highlights Eli Lilly’s growth momentum while arguing the company’s expansion could extend beyond its GLP-1 franchise.
THE APEX TIMES
A new report highlighted clinical research around Zepbound, a weight-loss medicine linked to Eli Lilly, arguing the findings could matter to investor sentiment, even as key trial details were not provided in the post.
THE APEX TIMES
Market commentary tied recent gains in Salior Therapeutics (SLS) and ImmunityBio (IBRX) to a renewed perception that Big Pharma is willing to pay premium prices for immune-focused platforms, pointing to Eli Lilly’s latest reported deal value.
